

PAPER

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *Nanoscale Adv.*, 2025, 7, 6110

Structural engineering of silver nanoparticles for enhanced photoacoustic imaging

Rui Zhang,^a Manuel Dias,^{ab} Yanchen Li,^a Stephan Rütten,^c Fabian Kiessling,^a Twan Lammers^a and Roger M. Pallares^{*a}

Photoacoustic (PA) imaging is a diagnostic tool widely explored in (pre)clinical settings, as it combines the strengths of optical and ultrasound imaging, resulting in high contrast resolution and deep tissue penetration. Although PA imaging can directly visualize some endogenous molecules (e.g. deoxygenated and oxygenated hemoglobin), most of its applications require the administration of external probes, including organic dyes and inorganic nanoparticles. Despite being historically used for antimicrobial and wound healing applications, silver nanoparticles (AgNPs) possess clear merits for PA imaging, including tunable optical properties, high-quality localized surface plasmon (LSP) resonances, strong photothermal conversions, and photostability. In this study, we explored new PA imaging probes based on silver nanocores (with different morphologies and sizes) and polymer shells, and identified the structural features that provide improved biocompatibility, stability, and probe performance. Notably, the size and morphology of the cores strongly impacted the PA signal of the silver probes. For example, among the different particles tested, plate-shaped AgNPs generated up to 3-fold greater signal, as their optical properties, specifically LSP bands and extinction coefficients, were better suited for PA imaging. Even if nanoconstructs displayed apparent inadequate optical features, e.g. in the case of spherical AgNPs with LSP bands centered in the blue region of the spectrum, a strong PA signal could still be obtained by manipulating the core size, resulting in up to 2-fold greater signal for larger particles in comparison to their smaller counterparts. All AgNPs were stable in biological environments, did not photobleach, and preserved strong PA imaging signals in *ex vivo* setups. Taken together, our results exemplify the merits of AgNPs as PA imaging agents, providing a better understanding of the nanoengineering of new imaging probes and thereby extending the applications of AgNPs beyond traditional antimicrobial and wound healing applications. Since some of the nanoconstructs we explored in this study are currently being investigated as photothermal agents in clinical trials, new opportunities may arise in intraoperative imaging and image-guided therapy.

Received 30th June 2025
Accepted 12th August 2025

DOI: 10.1039/d5na00636h

rsc.li/nanoscale-advances

Introduction

Photoacoustic (PA) or optoacoustic imaging is a non-invasive imaging modality which has been widely explored in preclinical research and has recently been translated into clinical practice.^{1–6} PA signal is generated by irradiated chromophores or probes that absorb the energy of non-ionizing laser pulses and convert it into local heat, generating ultrasound waves.^{7,8} Acoustic signals can provide better resolution than fluorescence, as they are less sensitive to scattering when propagating through tissues.^{9,10} Additionally, some endogenous molecules, such as oxygenated and deoxygenated hemoglobin, possess

characteristic PA signals, showing clinical potential to measure blood oxygen saturation as a disease marker.^{11,12} Nevertheless, (pre)clinical PA imaging faces key challenges, including low signal from many natural endogenous chromophores and limited spectral separation between them.^{12–14} To address this gap, near-infrared (NIR) absorbing organic dyes are frequently used as exogenous PA probes;^{15–17} however, they are limited by severe photobleaching, low NIR absorbance, poor light-to-acoustic signal transduction, and insufficient solubility and stability under biological conditions.^{13,18,19} Hence, there is an increasing need for superior exogenous PA probes that provide strong contrast at depth, remain stable during imaging, and are biocompatible.

In the last decade, noble metal (especially gold) nanoparticles have become increasingly adopted as PA imaging probes in preclinical settings because of their unique optoelectronic properties.^{20–22} Noble metal nanoparticles sustain localized surface plasmon (LSP) resonances, which result in

^aInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Aachen 52074, Germany. E-mail: rmoltopallar@ukaachen.de^bDepartment of Physics, Faculty of Science, University of Lisboa, 1500-274-Lisboa, Portugal^cElectron Microscope Facility, RWTH Aachen University Hospital, Aachen 52074, Germany

strong extinction coefficients and electromagnetic fields at their surfaces.^{23,24} The LSP bands can be shifted towards the NIR by manipulating the size and morphology of the nanoparticles.^{25–29} Moreover, they also display large photothermal conversion coefficients, and their surface can be functionalized with ligands, improving their biocompatibility.^{21,24,30} As a result, anisotropic gold nanoparticles, such as rods and shells, have already moved to clinical trials for photothermal ablation of prostate cancer and atherosclerosis plaque removal,^{31,32} and gold nanostars and rods have been explored preclinically for PA imaging.^{20,33,34} In the case of silver nanoparticles (AgNPs), despite displaying better quality LSP resonances than any other metal nanoparticle,³⁵ their uses have been historically limited to antimicrobial and wound healing applications.^{36–38} This has been partially caused by the poor control over their morphology (and optical properties) *via* traditional colloidal methods.³⁹ Nevertheless, chemical protocols developed in the last decade have significantly improved the structure manipulation of silver colloids, yielding anisotropic AgNPs with well-defined optoelectronic properties and endowing their use in other applications historically limited to anisotropic gold nanoparticles.^{40–42} As a result, there is a renewed interest in exploring anisotropic AgNPs in photothermal-related applications,^{43–45} such as photothermal therapy and PA imaging, where high-quality LSP can be beneficial for enhanced performance. For example, silver nanoplates have demonstrated excellent performance as PA agents, even under *in vivo* conditions.⁴⁶ Although various silver nanostructure morphologies can be synthetically obtained, a direct comparative analysis of differently shaped nanoconstructs has not yet been performed. Such a study would help to identify the most effective candidates for PA imaging applications.

In this study, we explored the use of five AgNPs made of different silver core structures (plates, cubes and spheres) and

sizes (ranging from 50 to 100 nm), and functionalized with a polymeric shell for PA imaging. Plate-shaped AgNPs displayed stronger PA responses than spherical and cubic AgNPs. Both larger-sized silver nanoplates and spherical silver particles presented greater PA contrast abilities compared to their smaller counterparts. The AgNPs preserved their PA performances in complex biological environments as demonstrated by the successful *ex vivo* PA imaging in deceased mice. Our results highlight the capabilities of silver nanomaterials in PA imaging, paving the way for their use in preclinical diagnosis.

Results and discussion

We explored five different AgNPs made of silver cores and polyvinylpyrrolidone (PVP) shells (Fig. 1a). PVP acted as the stabilizing agent and was chosen because it is a polymer commonly used in drug delivery applications, including in some clinical silver nanomedicines, such as Argovit.³⁷ Two nanoconstructs had spherical cores with sizes of 50 and 100 nm (50 nm and 100 nm SP, respectively), as these are sizes commonly used in therapeutic AgNPs.^{47,48} The other three nanoparticles had anisotropic cores, consisting of two particles absorbing at the end of the visible light range, namely 40 nm silver plate (40 nm PL) and 100 nm silver cube (100 nm CB), and one NIR-absorbing 65 nm silver plate (65 nm PL). The latter one is used in the clinical formulation SNA-001, which is currently being explored for photothermal treatments against skin conditions.³⁷

The AgNPs were relatively monodisperse, except for the 65 nm PL, which showed a broad range of sizes (Fig. 1b and Table S1). This was consistent with previous studies, which reported that silver nanoplates (particularly those with larger sizes) tend to be highly heterogeneous, due to challenges on limiting their growth to two dimensions and the simultaneous




Fig. 1 Characterization of the AgNPs. (a) Transmission electron micrographs, (b) Feret diameter distributions, (c) extinction spectra, and (d) FTIR spectra of the silver nanoconstructs.



growth of seed-mediated and seedless nanoconstructs.^{49–51} Elemental mapping with energy-dispersive X-ray spectroscopy (EDS) confirmed that all nanoparticles were composed of silver cores (Fig. S1).

Because of their distinct morphologies and sizes, the AgNPs displayed rather different optical properties (Fig. 1c), with LSP band maximum ranging from 426 nm (50 nm SP) to 814 nm (65 nm PL). This nanoconstruct selection allowed to obtain different AgNPs with LSP bands covering the light spectrum from visible to NIR. Notably, 100 nm SP had relatively large extinction in the NIR (despite being spherical) because of its broad LSP band due to its large core size. The presence of PVP on the AgNP surface was confirmed by Fourier-transform infrared (FTIR) spectroscopy, as multiple characteristic PVP peaks were observed (Fig. 1d). For example, the peaks at 1270 and 1420 cm^{-1} were associated with the stretching vibration of C–N, the peak at 1650 cm^{-1} was related to the stretching vibration of C=N, while the peaks at 2890 cm^{-1} and 3400 cm^{-1} were related to the C–H stretching and N–H vibration,

respectively. Furthermore, the AgNPs had zeta potentials between -10.6 and -13.6 mV, which were consistent with the ones obtained for metallic nanoparticles coated with PVP,^{52,53} and could be dispersed well in water as indicated by their hydrodynamic diameters (Fig. S2).

Interestingly, coating the silver cores with PVP had an additional advantage. PVP is commonly used as a cryoprotectant agent during the lyophilization of pharmaceuticals and nanomedicines.^{54–56} Lyophilization is a low-temperature dehydration process that removes water by sublimation. This process improves the long-term stability of medicines and decreases their volume and weight, easing their storage and commercialization. The five AgNPs could be lyophilized and resuspended in water without the need of adding any additional cryoprotective reagent, as demonstrated by their optical properties (LSP band position) and hydrodynamic diameters, which were preserved after lyophilization and reconstitution without significant changes (Fig. 2). As expected, for most nanoconstructs, their hydrodynamic diameters were significantly




Fig. 2 Effect of lyophilization on the AgNP properties. (a) Photographs of the AgNPs before and after lyophilization, and after reconstitution with water. (b) Extinction spectra, (c) LSP band positions, and (d) hydrodynamic diameters (HD) of AgNPs before and after lyophilization. Solid lines represented AgNPs before lyophilization, dashed lines represented AgNPs after lyophilization. Values in columns represent mean $\pm$ standard deviation. All measurements were performed in triplicate.






Fig. 3 PA-US imaging of the AgNPs in gelatin phantoms. PA-US images, PA spectra, and PA intensities at 705 nm of (a–c) 50 nm SP, (d–f) 100 nm SP, (g–i) 40 nm PL, (j–l) 65 nm PL, and (m–o) 100 nm CB in gelatin phantoms at different silver concentrations (from 0 to 200 μM silver). The scale bar is displayed in linear arbitrary units. Values in columns represent mean $\pm$ standard deviation. All measurements were performed in triplicate. All measurements were performed roughly at the same time, and the 0 μM silver samples are the same for the five nanoconstructs.



larger than their average core sizes as measured by transmission electron microscopy, since the former include the core sizes and the ligand and hydration shells of the particles. In the case of the silver plates, however, those differences were less pronounced, likely due to their strong anisotropy, since the silver nanoplates were flat (pseudo two dimensional) particles with only 10 nm thickness,^{57,58} rather than three dimensional objects (like spheres or cubes). Notably, all AgNPs displayed good long-term stability, as demonstrated by their unaltered LSP band positions and hydrodynamic diameters during five weeks after reconstitution (Fig. S3).

Next, we evaluated the PA imaging capabilities of the five silver nanoconstructs. The AgNPs were imaged at different concentrations (ranging from 0 to 200 μM silver) in gelatin phantoms with a preclinical PA system that provided both bright-mode ultrasound (US) and PA (from 680 to 970 nm) (Fig. 3). While the 50 nm SP displayed relatively low PA responses (up to 0.40 ± 0.01 at 200 μM silver), which was expected based on their LSP band centered at 426 nm, the 100 nm SP did show considerably greater PA intensities (up to 0.71 ± 0.03 at 200 μM silver). Even though the LSP band of the larger spherical particles was centered at 478 nm, the plasmonic band was very broad due to the large core sizes, providing significant absorption in the NIR region (from 650 to 800 nm), and contributing to the strong PA contrast. Similarly, the 65 nm PL exhibited stronger PA responses than the 40 nm PL (up to 1.01 ± 0.03 and 0.89 ± 0.02 , respectively, at 200 μM silver), as the former displayed greater extinction (LSP band maximum at

814 nm and 536 nm, respectively) in the area where the PA spectra were recorded. Interestingly, the 65 nm PL displayed a more spread PA signal in the phantom, which might have been caused by the broader size distribution of the particles compared to other AgNPs (Fig. 1b). Lastly, even though the 100 nm CB LSP band had a certain overlap within the NIR region, its intensity was very weak (Fig. S4), resulting in this nanoconstruct displaying the lowest PA responses among all particles (up to 0.35 ± 0.03 at 200 μM silver). It is worth noting that the PA intensities depend on multiple factors, including the position and intensity of the plasmon bands and absorption coefficients of the particles. Because the experiments were performed at fixed amounts of silver, larger particles, such as 100 nm CB, were present at lower (particle) concentrations, resulting in lower overall extinctions. Furthermore, large particles, such as 100 nm CB, display significantly greater scattering cross sections than absorption cross sections, being less efficient at absorbing incident photons and converting them into heat. Notably, for all five AgNPs, no noticeable loss of PA signal intensity was observed over 10 min continuous irradiations at 705 nm, highlighting the photostability and robustness of the silver probes (Fig. S5). The stability assays for all nanoconstructs were performed under the same exposure conditions for better comparison, and the excitation wavelength of 705 nm was chosen because all nanoparticles displayed (moderated to very strong) PA responses in that wavelength.

As new silver nanomedicines are progressively moving into clinical trials, and the PVP-coated AgNPs explored in this study




Fig. 4 *In vitro* assessment of the AgNPs. Cell viability of (a) Hepa 1–6 cells and (b) HEK 293 cells after 24 h incubations with AgNPs (at 0 to 200 μM silver). (c) LSP band positions and (d) hydrodynamic diameter (HD) of the AgNPs at different incubation times in 10% FBS. Values represent mean $\pm$ standard deviation. All measurements were performed in triplicate.






Fig. 5 Ex vivo PA-US imaging of the AgNPs. PA-US images, PA spectra and PA intensities at 705 nm of (a–c) 50 nm SP, (d–f) 100 nm SP, (g–i) 40 nm PL, (j–l) 65 nm PL, and (m–o) 100 nm CB intramuscularly injected (50 μ L, 0 or 200 μ M silver) in the legs of mouse cadavers. The scale bar is displayed in linear arbitrary units. The regions of interest for the spectral acquisition are highlighted by yellow dashed areas in (a, d, g, j and m). Values represent mean $\pm$ standard deviation. All measurements were performed in triplicate.



are intended to be used as PA imaging probes, we assessed their biocompatibility *in vitro*. Two different cell lines commonly used in toxicological assays, namely mouse hepatoma cell line Hepa1-6 and human embryonic kidney (HEK) 293 cells, were used for the cytotoxicity assessment of the AgNPs. 50 nm SP and 100 nm CB did not show obvious cytotoxicity towards the two cell lines even under high concentrations (up to 200 μM silver) after 24 h (Fig. 4a and b). 100 nm SP and 65 nm PL induced some cytotoxicity (over 20% cell growth inhibition) but only to HEK 293 cells and under high silver concentration (100 and/or 200 μM silver). Among the five nanoformulations, 40 nm PL affected cell viability the most (primarily to HEK 293 cells), as around 20% growth inhibition was observed at 25 μM silver. These results were consistent with previous literature focused on other therapeutic silver nanoconstructs,⁵⁹ which indicated that polymer-functionalized AgNPs were overall not acutely toxic. To further characterize the behavior of the AgNPs in complex biological environments, their stability in 10% fetal bovine serum (FBS) was assessed. Notably, no significant variations were observed in the LSP band positions and hydrodynamic diameters of the particles up to 96 h, indicating that the AgNPs were stable in the complex biological environment (Fig. 4c and d).

Lastly, encouraged by the outstanding PA responses of the AgNPs in gelatin and plastic tube phantoms, and their stability in biological environments, we assessed their PA imaging performance *ex vivo* (Fig. 5). Mouse cadavers from a previous experiment were repurposed for the *ex vivo* imaging, and therefore, no animals were sacrificed for the current study. The different AgNPs (50 μL , 200 μM silver) were intramuscularly injected into the legs of the deceased mice and imaged from 680 to 970 nm with a preclinical PA system. Consistent with the *in vitro* imaging, the 50 nm SP and 100 nm CB showed very weak PA responses (0.11 ± 0.01 and 0.10 ± 0.01 , respectively). Meanwhile, the 100 nm SP displayed moderate PA signal intensities (0.26 ± 0.01). Notably, the stronger PA signals of the two nanoplate formulations, 40 nm PL and 65 nm PL, were well preserved in the biological (*ex vivo*) environment (0.40 ± 0.01 and 0.62 ± 0.02 , respectively). The 65 nm PL had the strongest PA intensities, as these nanoconstructs were the only ones to display LSP bands centered in the NIR region and their LSP bands were more intense due to their morphology. It is worth noting that the current study focused on the impact of inherent features (*e.g.* shape, extinction, and LSP band position) of silver probes on their PA performance. Nevertheless, other (indirect) *in vivo* characteristics, such as biodistribution, pharmacokinetics, and pathological tissue targeting, are also important in defining the nanoconstruct performances and shall be evaluated in future studies to further demonstrate the advantages of silver nanomedicines over conventional small-molecule imaging agents.

Overall, these results demonstrate that AgNPs can be strong PA probes, and their intensity is strongly affected by their core morphology. Among the different AgNPs explored, the 65 nm PL exhibited the strongest PA contrasts because their LSP band was centered in the NIR and had the highest extinction. The PA responses of AgNPs were well-preserved in complex biological media and *ex vivo* environments. This study paves the way for future *in vivo* research, leveraging the PA properties of AgNPs to

gain deeper insights into the endogenous behavior of emerging silver nanomedicines during their (pre)clinical development, as well as broadens their potential applications, including intraoperative imaging and sentinel lymph node mapping.

Conclusion

We assessed the structural and optical characteristics that define the PA imaging performance of silver nanoconstructs. Five different probes, comprised of a silver (spherical, plate, or cube) core functionalized with a polymeric shell, were explored. The PVP-based polymer coating provided stability in biological environments and preserved the silver nanoconstruct properties after lyophilization. Among the different AgNP cores tested, the 65 nm PL exhibited the strongest PA contrast, because their LSP was centered in NIR and their highest extinction in that region. Furthermore, the PA contrast abilities of our AgNPs were preserved in biological environments, as exemplified by *ex vivo* imaging in deceased mice. Together, our results highlight the potential of silver nanoconstructs as PA imaging probes, which hold promise for further diagnostic applications, including intraoperative imaging and sentinel lymph node mapping.

Materials and methods

Materials

50 nm SP, 100 nm SP, 40 nm PL, 65 nm PL, and 100 nm CB were purchased from nanoComposix (USA). Dulbecco's modified Eagle's medium (DMEM, 4.5 g L⁻¹ glucose) and minimum essential medium (MEM) were obtained from Gibco (UK). Fetal bovine serum (FBS) was purchased from Pan-Biotech (Germany). XTT-based cell proliferation kit was purchased from Biological Industries (Israel). Deionized (DI) water was produced by a PURELAB flex 2 device (ELGA LabWater, Germany) and used for all experiments.

Characterization

An Infinite M200 Pro microplate reader (Tecan, Switzerland) was used to measure the extinction spectra of the AgNPs. The reader was set in absorbance scan mode with a scanning interval of 2 nm. A Nanosizer ZS (Malvern, UK) was used to determine the hydrodynamic diameter and zeta potential. A 100 kV transmission electron microscope system (Hitachi, Japan) was used to image the morphology. The composition of AgNPs was analyzed with a STEM-Detector using a scanning electron microscope (Quattro S, Thermo Fisher) at 30 kV acceleration voltage in a high vacuum. AgNPs were placed on carbon-film copper grids by drop-casting before the electron microscope imaging. A Spectrum 3 FTIR spectrometer (PerkinElmer, USA) was used to measure the Fourier-transform infrared (FTIR) spectra. Before FTIR analysis, the AgNPs were lyophilized with an Alpha 2-4 LD PLUS (Martin Christ, Germany).

Lyophilization

4 mL of each AgNP solution (200 μM silver) was rapidly frozen by immersing the sample in liquid nitrogen for 1 hour. The



samples were then subjected to freeze-drying under vacuum (Alpha 2–4 LD PLUS, Martin Christ, Germany) for 48 hours. The dried AgNPs were reconstituted with 4 mL of DI water by vigorously vortexing. To evaluate the shelf lives, all AgNPs were left undisturbed for up to 5 weeks after reconstitution. The extinction spectra were normalized for easier LSP band comparison between samples before and after lyophilization.

Stability in 10% FBS

The AgNPs were dispersed in 10% FBS aqueous solutions and left undisturbed. At each time point (0, 1, 3, 6, 12, 24, 48 and 96 h), their hydrodynamic diameter and extinction spectra were measured.

PA imaging

The PA imaging of the AgNPs was performed in gelatin phantoms using the VevoLAZR system (Visualsonics, Canada) equipped with an MX250 transducer. The MX250 transducer has an axial resolution of 75 μm and a total imageable area of up to 23 $\times$ 30 mm. To make the gelatin phantom, 40 g of gelatin was dissolved in 400 mL of warm DI water (40–50 $^{\circ}\text{C}$). The 10% (w/v) gelatin solution was poured into the mold and solidified at 4 $^{\circ}\text{C}$ overnight. To acquire the PA spectra, 0.3 mL of each AgNP solution (0, 50, 100, 200 μM silver, 2% (w/v) gelatin) was added into the sample hole (<10 mm $\times$ 10 mm) in the 10% (w/v) gelatin phantom, left to solidify for 5 h at 4 $^{\circ}\text{C}$, and then imaged in the spectra acquisition mode with excitation wavelengths from 680 to 970 nm. The PA stability of the AgNPs was performed in low-density polyethylene tubes, saturated with 0.05 mL of each silver nanoparticle solution (200 μM silver). The PA intensity was recorded under 10 min continuous excitation at the single wavelength (705 nm) mode. All PA measurements were performed in triplicate (in three different samples).

To evaluate the PA intensity, the active signal areas in the PA images were selected as the region of interest (ROI). The system determined the total signal intensity within the ROI by adding up the active pixel values in the ROI and then averaging this sum over the total number of pixels within the same ROI. The resulting value was expressed as PA intensity.

Cytotoxicity studies

The *in vitro* cytotoxicity test was performed with the human embryonic kidney (HEK) 293 cells and mouse hepatoma cell line Hepa1-6 obtained from the DSMZ-German Collection of Microorganisms and Cell Cultures (Germany). Hepa 1–6 cells were cultured in DMEM (4.5 g L^{−1} glucose) supplemented with 10% FBS and 1% penicillin/streptomycin. HEK 293 cells were cultured in MEM supplemented with 10% FBS and 1% penicillin/streptomycin. Both cell lines with a density of 10 000 cells per well were cultured at 37 $^{\circ}\text{C}$ with 5% CO₂ for 12 h in a 96-well plate. Subsequently, the cells were exposed to AgNP treatments with different concentrations (0, 3.13, 6.25, 12.50, 25.00, 50.00, 100.00 and 200.00 μM silver) and cultured for 24 h. The standard tetrazolium chloride (XTT) assay was performed to determine cell proliferation.

Ex vivo PA imaging

As a control, PA imaging of the legs of mouse cadavers was performed under the VevoLAZR system and the PA spectra were acquired with excitation wavelengths from 680 to 970 nm. 50 μL AgNPs (200 μM silver) were intramuscularly injected into the legs and then imaged with the same settings. The deceased mice were repurposed from a previous experiment and therefore, no additional animals were sacrificed. The previous animal experiment had been carried out under the authorization of the German State Office for Nature, Environment, and Consumer Protection (LANUV, Germany) and complied with institutional guidelines, EU Directive 2010/63/EU, and German federal animal protection laws.

Conflicts of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Data availability

The data supporting this article have been included as part of the SI.

Size distributions of the silver nanoparticles; energy-dispersive X-ray spectroscopy (EDS) micrographs of the silver nanoparticles; characterizations of the silver nanoparticles; extinction spectra of the silver nanostructures; PA stability of the silver nanoparticles over time in polyethylene tubes (PDF). See DOI: <https://doi.org/10.1039/d5na00636h>.

Acknowledgements

Financial & competing interests disclosure. This work is funded by the Federal Ministry of Education and Research (BMBF), by the Ministry of Culture and Science of the German State of North Rhine-Westphalia under the Excellence Strategy of the Federal Government and the Länder through the RWTH Junior Principal Investigator (JPI) fellowship scheme, by the European Research Council (ERC; 864121), and by the German Research Foundation (DFG; GRK2375 (331065168), FOR5011, SFB1066 and 495328185). The Quattro S was funded by the German Research Foundation (DFG, 495328185).

References

- 1 D. J. Grootendorst, R. M. Fratila, M. Visscher, B. T. Haken, R. J. A. van Wezel, S. Rottenberg, W. Steenbergen, S. Manohar and T. J. M. Ruers, Intra-operative *ex vivo* photoacoustic nodal staging in a rat model using a clinical superparamagnetic iron oxide nanoparticle dispersion, *J. Biophot.*, 2013, **6**(6–7), 493–504.
- 2 J. Kim, S. Park, Y. Jung, S. Chang, J. Park, Y. Zhang, J. F. Lovell and C. Kim, Programmable Real-time Clinical



- Photoacoustic and Ultrasound Imaging System, *Sci. Rep.*, 2016, **6**(1), 35137.
- 3 W. Choi, E.-Y. Park, S. Jeon and C. Kim, Clinical photoacoustic imaging platforms, *Biomed. Eng. Lett.*, 2018, **8**(2), 139–155.
 - 4 L. Lin and L. V. Wang, The emerging role of photoacoustic imaging in clinical oncology, *Nat. Rev. Clin. Oncol.*, 2022, **19**(6), 365–384.
 - 5 A. B. E. Attia, G. Balasundaram, M. Moothanchery, U. S. Dinish, R. Bi, V. Ntziachristos and M. Olivo, A review of clinical photoacoustic imaging: Current and future trends, *Photoacoustics*, 2019, **16**, 100144.
 - 6 J. Park, S. Choi, F. Knieling, B. Clingman, S. Bohndiek, L. V. Wang and C. Kim, Clinical translation of photoacoustic imaging, *Nat. Rev. Bioeng.*, 2025, **3**(3), 193–212.
 - 7 L. V. Wang and S. Hu, Photoacoustic Tomography: *In Vivo* Imaging from Organelles to Organs, *Science*, 2012, **335**(6075), 1458–1462.
 - 8 Q. Fu, R. Zhu, J. Song, H. Yang and X. Chen, Photoacoustic Imaging: Contrast Agents and Their Biomedical Applications, *Adv. Mater.*, 2019, **31**(6), 1805875.
 - 9 S. Hu and L. Wang, Photoacoustic imaging and characterization of the microvasculature, *J. Biomed. Opt.*, 2010, **15**(1), 011101.
 - 10 V. H. M. Doan, V. T. Nguyen, S. Mondal, T. M. T. Vo, C. D. Ly, D. D. Vu, G. Y. Ataklti, S. Park, J. Choi and J. Oh, Fluorescence/photoacoustic imaging-guided nanomaterials for highly efficient cancer theragnostic agent, *Sci. Rep.*, 2021, **11**(1), 15943.
 - 11 H. F. Zhang, K. Maslov, M. Sivaramakrishnan, G. Stoica and L. V. Wang, Imaging of hemoglobin oxygen saturation variations in single vessels *in vivo* using photoacoustic microscopy, *Appl. Phys. Lett.*, 2007, **90**(5), 053901.
 - 12 C. Kim, C. Favazza and L. V. Wang, *In vivo* photoacoustic tomography of chemicals: high-resolution functional and molecular optical imaging at new depths, *Chem. Rev.*, 2010, **110**(5), 2756–2782.
 - 13 J. Weber, P. C. Beard and S. E. Bohndiek, Contrast agents for molecular photoacoustic imaging, *Nat. Methods*, 2016, **13**(8), 639–650.
 - 14 Z. Chen, I. Gezginer, Q. Zhou, L. Tang, X. L. Deán-Ben and D. Razansky, Multimodal optoacoustic imaging: methods and contrast materials, *Chem. Soc. Rev.*, 2024, **53**(12), 6068–6099.
 - 15 H.-B. Cheng, Y. Li, B. Z. Tang and J. Yoon, Assembly strategies of organic-based imaging agents for fluorescence and photoacoustic bioimaging applications, *Chem. Soc. Rev.*, 2020, **49**(1), 21–31.
 - 16 R. A. Barmin, M. Moosavifar, R. Zhang, S. Rütten, S. Thoröe-Boveleth, E. Rama, T. Ojha, F. Kiessling, T. Lammers and R. M. Pallares, Hybrid ultrasound and photoacoustic contrast agent designs combining metal phthalocyanines and PBCA microbubbles, *J. Mater. Chem. B*, 2024, **12**(10), 2511–2522.
 - 17 S. Jiang, J. Lin and P. Huang, Nanomaterials for NIR-II Photoacoustic Imaging, *Adv. Healthcare Mater.*, 2023, **12**(16), 2202208.
 - 18 Y. Liu, L. Teng, B. Yin, H. Meng, X. Yin, S. Huan, G. Song and X.-B. Zhang, Chemical Design of Activatable Photoacoustic Probes for Precise Biomedical Applications, *Chem. Rev.*, 2022, **122**(6), 6850–6918.
 - 19 W. Choi, B. Park, S. Choi, D. Oh, J. Kim and C. Kim, Recent Advances in Contrast-Enhanced Photoacoustic Imaging: Overcoming the Physical and Practical Challenges, *Chem. Rev.*, 2023, **123**(11), 7379–7419.
 - 20 W. Li and X. Chen, Gold nanoparticles for photoacoustic imaging, *Nanomedicine*, 2015, **10**(2), 299–320.
 - 21 J. Conde, G. Doria and P. Baptista, Noble Metal Nanoparticles Applications in Cancer, *J. Drug Delivery*, 2012, **2012**(1), 751075.
 - 22 M. Azharuddin, G. H. Zhu, D. Das, E. Ozgur, L. Uzun, A. P. F. Turner and H. K. Patra, A repertoire of biomedical applications of noble metal nanoparticles, *Chem. Commun.*, 2019, **55**(49), 6964–6996.
 - 23 K. M. Mayer and J. H. Hafner, Localized Surface Plasmon Resonance Sensors, *Chem. Rev.*, 2011, **111**(6), 3828–3857.
 - 24 P. K. Jain, X. Huang, I. H. El-Sayed and M. A. El-Sayed, Review of Some Interesting Surface Plasmon Resonance-enhanced Properties of Noble Metal Nanoparticles and Their Applications to Biosystems, *Plasmonics*, 2007, **2**(3), 107–118.
 - 25 K.-S. Lee and M. A. El-Sayed, Gold and Silver Nanoparticles in Sensing and Imaging: Sensitivity of Plasmon Response to Size, Shape, and Metal Composition, *J. Phys. Chem. B*, 2006, **110**(39), 19220–19225.
 - 26 C. J. Murphy, T. K. Sau, A. M. Gole, C. J. Orendorff, J. Gao, L. Gou, S. E. Hunyadi and T. Li, Anisotropic Metal Nanoparticles: Synthesis, Assembly, and Optical Applications, *J. Phys. Chem. B*, 2005, **109**(29), 13857–13870.
 - 27 R. Zhang, F. Kiessling, T. Lammers and R. M. Pallares, Unraveling the Seedless Growth of Gold Nanostars through Fractional Factorial Design, *J. Phys. Chem. C*, 2022, **126**(43), 18580–18585.
 - 28 P. Wu, R. Zhang, C. Porte, F. Kiessling, T. Lammers, S. Rezvantab, S. Miandoost and R. M. Pallares, Machine learning to predict gold nanostar optical properties, *Nanoscale Adv.*, 2025, **7**(13), 4117–4128.
 - 29 S. Sanjeev Ambady, R. Mihiyar, R. Zhang, M. Tiboni, A. Pricci, S. Thoröe-Boveleth, L. Casettari, F. Kiessling, J. M. Metselaar, T. Lammers and R. M. Pallares, Engineering the Structure and Optical Properties of Gold Nanostars with Microfluidics, *J. Phys. Chem. C*, 2025, **129**(21), 9819–9828.
 - 30 P. K. Jain, X. Huang, I. H. El-Sayed and M. A. El-Sayed, Noble metals on the nanoscale: Optical and photothermal properties and some applications in imaging, sensing, biology, and medicine, *Acc. Chem. Res.*, 2008, **41**(12), 1578–1586.
 - 31 R. Zhang, F. Kiessling, T. Lammers and R. M. Pallares, Clinical translation of gold nanoparticles, *Drug Delivery Transl. Res.*, 2023, **13**(2), 378–385.



- 32 L. Yao, D. Bojic and M. Liu, Applications and safety of gold nanoparticles as therapeutic devices in clinical trials, *J. Pharm. Anal.*, 2023, **13**(9), 960–967.
- 33 X. Huang, S. Neretina and M. A. El-Sayed, Gold Nanorods: From Synthesis and Properties to Biological and Biomedical Applications, *Adv. Mater.*, 2009, **21**(48), 4880–4910.
- 34 R. Zhang, S. Thorøe-Boveleth, D. N. Chigrin, F. Kiessling, T. Lammers and R. M. Pallares, Nanoscale engineering of gold nanostars for enhanced photoacoustic imaging, *J. Nanobiotechnol.*, 2024, **22**(1), 115.
- 35 M. G. Blaber, M. D. Arnold and M. J. Ford, A review of the optical properties of alloys and intermetallics for plasmonics, *J. Phys.: Condens. Matter*, 2010, **22**(14), 143201.
- 36 S. Medici, M. Peana, V. M. Nurchi and M. A. Zoroddu, Medical Uses of Silver: History, Myths, and Scientific Evidence, *J. Med. Chem.*, 2019, **62**(13), 5923–5943.
- 37 M. Dias, R. Zhang, T. Lammers and R. M. Pallares, Clinical translation and landscape of silver nanoparticles, *Drug Delivery Transl. Res.*, 2024, **15**, 789–797.
- 38 F. Paladini and M. Pollini, Antimicrobial Silver Nanoparticles for Wound Healing Application: Progress and Future Trends, *Materials*, 2019, **12**(16), 2540.
- 39 M. Rycenga, C. M. Cobley, J. Zeng, W. Li, C. H. Moran, Q. Zhang, D. Qin and Y. Xia, Controlling the Synthesis and Assembly of Silver Nanostructures for Plasmonic Applications, *Chem. Rev.*, 2011, **111**(6), 3669–3712.
- 40 Z. Chen, J. W. Chang, C. Balasanthiran, S. T. Milner and R. M. Rioux, Anisotropic Growth of Silver Nanoparticles Is Kinetically Controlled by Polyvinylpyrrolidone Binding, *J. Am. Chem. Soc.*, 2019, **141**(10), 4328–4337.
- 41 O. Pryshchepa, P. Pomastowski and B. Buszewski, Silver nanoparticles: Synthesis, investigation techniques, and properties, *Adv. Colloid Interface Sci.*, 2020, **284**, 102246.
- 42 A. Loiseau, V. Asila, G. Boitel-Aullen, M. Lam, M. Salmain and S. Boujday, Silver-Based Plasmonic Nanoparticles for and Their Use in Biosensing, *Biosensors*, 2019, **9**(2), 78.
- 43 S. Kaur, R. Tambat, V. Pathania, H. Nandanwar and S. Soni, Photo-thermally enhanced antimicrobial efficacy of silver nanoplates against Gram-negative, Gram-positive bacterial and fungal pathogens, *J. Appl. Microbiol.*, 2022, **133**(2), 569–578.
- 44 V. O. Shipunova, M. M. Belova, P. A. Kotelnikova, O. N. Shilova, A. B. Mirkasymov, N. V. Danilova, E. N. Komedchikova, R. Popovtzer, S. M. Deyev and M. P. Nikitin, Photothermal Therapy with HER2-Targeted Silver Nanoparticles Leading to Cancer Remission, *Pharmaceutics*, 2022, **14**(5), 1013.
- 45 M. B. Rivas Aiello, J. C. Azcárate, E. Zelaya, P. David Gara, G. N. Bosio, T. Gensch and D. O. Mártire, Photothermal therapy with silver nanoplates in HeLa cells studied by *in situ* fluorescence microscopy, *Biomater. Sci.*, 2021, **9**(7), 2608–2619.
- 46 K. A. Homan, M. Souza, R. Truby, G. P. Luke, C. Green, E. Vreeland and S. Emelianov, Silver Nanoplate Contrast Agents for *in Vivo* Molecular Photoacoustic Imaging, *ACS Nano*, 2012, **6**(1), 641–650.
- 47 L. Xu, Y.-Y. Wang, J. Huang, C.-Y. Chen, Z.-X. Wang and H. Xie, Silver nanoparticles: Synthesis, medical applications and biosafety, *Theranostics*, 2020, **10**(20), 8996.
- 48 A. Nene, M. Galluzzi, L. Hongrong, P. Somani, S. Ramakrishna and X.-F. Yu, Synthetic preparations and atomic scale engineering of silver nanoparticles for biomedical applications, *Nanoscale*, 2021, **13**(33), 13923–13942.
- 49 S. Chen and D. L. Carroll, Synthesis and Characterization of Truncated Triangular Silver Nanoplates, *Nano Lett.*, 2002, **2**(9), 1003–1007.
- 50 S. Chen and D. L. Carroll, Silver Nanoplates: Size Control in Two Dimensions and Formation Mechanisms, *J. Phys. Chem. B*, 2004, **108**(18), 5500–5506.
- 51 A. U. Khan, Z. Zhou, J. Krause and G. Liu, Poly(vinylpyrrolidone)-Free Multistep Synthesis of Silver Nanoplates with Plasmon Resonance in the Near Infrared Range, *Small*, 2017, **13**(43), 1701715.
- 52 V. Ramalingam, K. Varunkumar, V. Ravikumar and R. Rajaram, Target delivery of doxorubicin tethered with PVP stabilized gold nanoparticles for effective treatment of lung cancer, *Sci. Rep.*, 2018, **8**(1), 3815.
- 53 S. Ahlberg, A. Antonopoulos, J. Diendorf, R. Dringen, M. Eppe, R. Flöck, W. Goedecke, C. Graf, N. Haberl, J. Helmlinger, F. Herzog, F. Heuer, S. Hirn, C. Johannes, S. Kittler, M. Köller, K. Korn, W. G. Kreyling, F. Krombach, J. Lademann, K. Loza, E. M. Luther, M. Malissek, M. C. Meinke, D. Nordmeyer, A. Pailliant, J. Raabe, F. Rancan, B. Rothen-Rutishauser, E. Rühl, C. Schleh, A. Seibel, C. Sengstock, L. Treuel, A. Vogt, K. Weber and R. Zellner, PVP-coated, negatively charged silver nanoparticles: A multi-center study of their physicochemical characteristics, cell culture and *in vivo* experiments, *Beilstein J. Nanotechnol.*, 2014, **5**, 1944–1965.
- 54 Z. Xi, R. Zhang, S. Thorøe-Boveleth, F. Kiessling, T. Lammers and R. M. Pallares, Improving Lyophilization and Long-Term Stability of Gold Nanostars for Photothermal Applications, *ACS Appl. Nano Mater.*, 2023, **6**(18), 17336–17346.
- 55 T. Ojha, V. Pathak, N. Drude, M. Weiler, D. Rommel, S. Rütten, B. Geinitz, M. J. van Steenbergen, G. Storm, F. Kiessling and T. Lammers, Shelf-Life Evaluation and Lyophilization of PBCA-Based Polymeric Microbubbles, *Pharmaceutics*, 2019, **11**(9), 433.
- 56 A. Parnsubsakul, C. Sapharoenkun, C. Warin, S. Ekgasit and P. Pienpinijtham, Selection of cryoprotectants for freezing and freeze-drying of gold nanoparticles towards further uses in various applications, *Colloids Surf., B*, 2022, **217**, 112702.
- 57 nanoComposix Peak λ 660 nm Silver Nanoplates - nanoComposix. <https://nanocomposix.com/products/peak-wavelength-660-nm-silver-nanoplates>, accessed December 3, 2024.
- 58 nanoComposix Peak λ 800 nm Silver Nanoplates - nanoComposix. <https://nanocomposix.com/products/peak-wavelength-800-nm-silver-nanoplates>, accessed December 3, 2024.
- 59 M. Akter, M. T. Sikder, M. M. Rahman, A. K. M. A. Ullah, K. F. B. Hossain, S. Banik, T. Hosokawa, T. Saito and M. Kurasaki, A systematic review on silver nanoparticles-induced cytotoxicity: Physicochemical properties and perspectives, *J. Adv. Res.*, 2018, **9**, 1–16.

